Jinhe Ebitda from 2010 to 2024

002688 Stock   4.38  0.16  3.52%   
Jinhe Biotechnology's EBITDA is increasing over the years with slightly volatile fluctuation. EBITDA is expected to dwindle to about 356.4 M. From 2010 to 2024 Jinhe Biotechnology EBITDA quarterly data regression line had arithmetic mean of  298,538,686 and r-squared of  0.70. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
369.5 M
Current Value
356.4 M
Quarterly Volatility
47.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Jinhe Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jinhe Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 8.6 M, Selling General Administrative of 167.5 M or Total Revenue of 1.5 B, as well as many indicators such as . Jinhe financial statements analysis is a perfect complement when working with Jinhe Biotechnology Valuation or Volatility modules.
  
This module can also supplement various Jinhe Biotechnology Technical models . Check out the analysis of Jinhe Biotechnology Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jinhe Stock

Jinhe Biotechnology financial ratios help investors to determine whether Jinhe Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jinhe with respect to the benefits of owning Jinhe Biotechnology security.